CVLCX | RIRCX | CVLCX / RIRCX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 28 years | 22 years | - |
Gain YTD | 20.158 | 10.702 | 188% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 250 | 1,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 260M | 108B | 0% |
Annual Yield % from dividends | 0.21 | 2.97 | 7% |
Returns for 1 year | 24.43 | 18.35 | 133% |
Returns for 3 years | -0.87 | 11.43 | -8% |
Returns for 5 years | 42.23 | 29.20 | 145% |
Returns for 10 years | 10.38 | 35.41 | 29% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DGEYX | 20.74 | 0.09 | +0.44% |
BNY Mellon Global Emerging Mkts - Y | |||
PGTIX | 18.68 | 0.04 | +0.21% |
T. Rowe Price Global Technology I | |||
VAGVX | 27.75 | -0.10 | -0.36% |
Vanguard Advice Select Global Value Adml | |||
MSCUX | 12.20 | -0.08 | -0.65% |
Morgan Stanley American Resilience A | |||
RYOAX | 66.30 | -0.54 | -0.81% |
Rydex Biotechnology H |